2023
Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension
Rabiee A, Cornman-Homonoff J, Kunstman J, Garcia-Tsao G, Taddei T. Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension. Current Hepatology Reports 2023, 22: 269-275. DOI: 10.1007/s11901-023-00617-4.Peer-Reviewed Original ResearchPortal hypertensionInterventional radiologyNon-cirrhotic portal hypertensionPorto-sinusoidal vascular diseaseHepatic sinusoidal obstruction syndromeAbsence of cirrhosisPortal vein thrombosisSinusoidal obstruction syndromeBudd-Chiari syndromeSurgical treatment optionsHepatic vascular anatomyObstruction syndromeVein thrombosisSurgical treatmentTreatment optionsVascular diseaseImproved outcomesTherapeutic evaluationVascular anatomyHeterogenous groupHypertensionSyndromeDisordersOutcomesTreatment
2021
Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. The American Journal Of Gastroenterology 2021, 116: 1913-1923. PMID: 33989225, PMCID: PMC8410631, DOI: 10.14309/ajg.0000000000001280.Peer-Reviewed Original ResearchConceptsLiver-related deathPrimary biliary cholangitisUDCA responseHepatic decompensationHepatocellular carcinomaUrsodeoxycholic acidUDCA respondersPortal hypertensionPartial respondersBiliary cholangitisTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityRetrospective cohort studyProportional hazards modelPBC cirrhosisCompensated cirrhosisCohort studyMale patientsClinical benefitUnadjusted ratesCirrhosisReduced mortalityDecompensationSACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchConceptsHepatic decompensationPortal hypertensionEvents of decompensationHepatic decompensation eventsLiver-related deathSignificant portal hypertensionAcceptable safety profileProspective human studiesRole of statinsChronic liver diseaseClasses of medicationsPatient-reported outcomesDevelopment of decompensationEffect of simvastatinVA Medical CenterCompensated cirrhosisDecompensation eventsStatin therapyVariceal hemorrhageCirrhotic patientsStandard therapyVascular reactivityExert pleiotropic effectsLiver diseaseRetrospective study
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrials
2012
PPARα activation in portal hypertension
Liu H, Lee S, Groszmann R, Iwakiri Y, Taddei T. PPARα activation in portal hypertension. Hepatology 2012, 56: 1993-1995. PMID: 23115009, DOI: 10.1002/hep.26045.Peer-Reviewed Original ResearchHepatic endothelial cellsHepatic endothelial dysfunctionPortal blood flowPortal hypertensionCyclo-oxygenase-1PPARa activatorPortal pressureSirius Red staining of liver sectionsEndothelial dysfunctionHepatic fibrosisVasodilatory response to acetylcholineRats treated with fenofibrateStaining of liver sectionsResponse to acetylcholineTreated with vehicleDevelopment of cirrhosisSmooth muscle actinCollagen I mRNA expressionNitric oxideCyclo-oxygenase-1 expressionAcetylcholine (AChCirrhotic rat liversOral fenofibrateCirrhotic ratsCGMP levelsExploring beyond cirrhosis
Pinzani M, Groszmann R, Iwakiri Y, Taddei T. Exploring beyond cirrhosis. Hepatology 2012, 56: 778-780. PMID: 22833249, DOI: 10.1002/hep.25775.Peer-Reviewed Original ResearchChronic liver diseaseLiver diseaseComplications of portal hypertensionNatural history of cirrhosisHistory of cirrhosisStage of chronic liver diseaseTreatment of chronic liver diseaseAdvanced stage of chronic liver diseaseGrade of activityAdverse prognosisPortal hypertensionLiver failureHepatocellular carcinomaClinicopathological assessmentStudy groupCirrhosisRisk factorsNatural historyDiseaseEnd stage